PARIS--A new venture capital investment fund, Auriga, was launched last week with plans to invest half of its $400 million in startup capital in life sciences companies, including businesses in genomics and biotechnology. The other half of the fund will be dedicated to information technology, the fund's managers announced. The fund aims to become a benchmark in Europe for financing new high-tech companies, they said.